BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23280874)

  • 1. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.
    Cai H; Chen MS; Sun ZY; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2013 Jun; 52(23):6106-10. PubMed ID: 23616304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
    Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of MUC1-lipopeptide chimeras.
    Wilkinson BL; Malins LR; Chun CK; Payne RJ
    Chem Commun (Camb); 2010 Sep; 46(34):6249-51. PubMed ID: 20664875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
    Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
    Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
    Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
    J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
    Renaudet O; BenMohamed L; Dasgupta G; Bettahi I; Dumy P
    ChemMedChem; 2008 May; 3(5):737-41. PubMed ID: 18205167
    [No Abstract]   [Full Text] [Related]  

  • 15. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
    Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
    ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
    Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
    Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
    Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.